These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26014348)

  • 1. Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.
    Pelkonen M; Luostari K; Tengström M; Ahonen H; Berdel B; Kataja V; Soini Y; Kosma VM; Mannermaa A
    BMC Cancer; 2015 May; 15():431. PubMed ID: 26014348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS3 is a novel poor prognostic factor for breast cancer.
    Rui X; Li Y; Jin F; Li F
    Int J Clin Exp Pathol; 2015; 8(5):5435-42. PubMed ID: 26191247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer.
    Luo P; Lu G; Fan LL; Zhong X; Yang H; Xie R; Lv Z; Lv QZ; Fu D; Yang LX; Ma Y
    Oncol Rep; 2017 Apr; 37(4):2057-2062. PubMed ID: 28260080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss.
    Guipponi M; Toh MY; Tan J; Park D; Hanson K; Ballana E; Kwong D; Cannon PZ; Wu Q; Gout A; Delorenzi M; Speed TP; Smith RJ; Dahl HH; Petersen M; Teasdale RD; Estivill X; Park WJ; Scott HS
    Hum Mutat; 2008 Jan; 29(1):130-41. PubMed ID: 17918732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
    Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.
    Tanaka M; Ichikawa-Tomikawa N; Shishito N; Nishiura K; Miura T; Hozumi A; Chiba H; Yoshida S; Ohtake T; Sugino T
    BMC Cancer; 2015 Feb; 15():53. PubMed ID: 25884418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
    Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
    Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of the transmembrane protease serine 3 mRNA level in radioresistant colorectal cancer tissues.
    Wen JY; Fang YY; Chen G; He RQ; Huang HQ; Wang RS; Zeng DT; Huang WJ; Qin XG
    Biomark Med; 2022 Jun; 16(9):693-715. PubMed ID: 35543030
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
    Michaelidou K; Ardavanis A; Scorilas A
    Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
    Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
    Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin expression predicts early recurrence in early-stage breast cancer.
    Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
    Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.
    Zheng M; Zhou Y; Yang X; Tang J; Wei D; Zhang Y; Jiang JL; Chen ZN; Zhu P
    Breast Cancer Res Treat; 2014 Nov; 148(2):423-36. PubMed ID: 25348432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
    Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
    Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer.
    Endo Y; Yamashita H; Takahashi S; Sato S; Yoshimoto N; Asano T; Hato Y; Dong Y; Fujii Y; Toyama T
    BMC Cancer; 2014 Dec; 14():990. PubMed ID: 25528056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
    Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer.
    Abba MC; Lacunza E; Nunez MI; Colussi A; Isla-Larrain M; Segal-Eiras A; Croce MV; Aldaz CM
    Biochim Biophys Acta; 2009 Oct; 1792(10):988-97. PubMed ID: 19616622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.